1. Home /
    2. Altai Protocol Library /
  2. New Drug: Oral relugolix for androgen-deprivation therapy in advanced prostate cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Drug: Oral relugolix for androgen-deprivation therapy in advanced prostate cancer

New Drug: Oral relugolix for androgen-deprivation therapy in advanced prostate cancer
Study:
  • Open-label, phase 3 trial
  • Candidates for >=1 yr of continuous androgen-deprivation therapy
  • Oral Relugolix (n=622) vs. leuprolide (n=308)
Efficacy:
  • Sustained testosterone suppression: 96.7% vs. 88.8% (non-inferior)
  • Probability of castration on day 4: 56% vs. 0%
  • PSA response on day 15: 79.4% vs. 19.8%
Safety:
  • Grade 3-4 AEs: 18.0% vs. 20.5%

N Engl J Med 2020;382:2187-96.

Shore ND, et al. Oral Relugolix for Androgen-Deprivation Therapy  in Advanced Prostate Cancer

https://doi.org/10.1056/NEJMoa2004325

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More